Home / Business and Economy / Merck KGaA Buys Bio-Techne for $11.3B

Merck KGaA Buys Bio-Techne for $11.3B

25 Jun

Summary

Merck KGaA is acquiring Bio-Techne Corp for $11.3 billion.
The deal includes a $73 per share offer, a 24% premium.
This acquisition will significantly expand Merck's life-science research.

Merck KGaA has announced its intention to acquire Bio-Techne Corp for an estimated $11.3 billion. This significant transaction aims to bolster Merck's position within the life-science research sector.

The proposed acquisition involves an offer of $73 per share for Bio-Techne, which translates to a notable 24% premium over the company's previous closing price. This deal is expected to be funded through a combination of Merck's existing cash reserves and newly acquired debt.

Bio-Techne is a key supplier of essential tools for scientific research, including reagents, proteins, and antibodies, as well as analytical instruments. Their integration into Merck is anticipated to create synergistic opportunities in drug development and scientific discovery.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.